Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.04% | 97.02% | 162.10% | 240.74% | 394.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.04% | 97.02% | 162.10% | 240.74% | 394.93% |
| Cost of Revenue | 15.30% | 7.85% | -2.06% | -5.66% | -4.43% |
| Gross Profit | 153.57% | 2,160.92% | 294.51% | 198.11% | 139.70% |
| SG&A Expenses | -5.17% | 0.05% | 17.54% | 44.84% | 61.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.65% | 3.57% | 7.94% | 18.18% | 24.33% |
| Operating Income | 53.92% | 68.10% | 62.57% | 48.88% | 36.92% |
| Income Before Tax | 46.46% | 62.64% | 59.16% | 49.67% | 39.93% |
| Income Tax Expenses | -34.01% | -45.50% | 401.71% | 453.37% | 885.99% |
| Earnings from Continuing Operations | 46.39% | 62.57% | 58.73% | 49.34% | 39.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.39% | 62.57% | 58.73% | 49.34% | 39.61% |
| EBIT | 53.92% | 68.10% | 62.57% | 48.88% | 36.92% |
| EBITDA | 54.16% | 68.34% | 62.77% | 49.04% | 37.05% |
| EPS Basic | 48.16% | 64.32% | 61.20% | 53.05% | 44.89% |
| Normalized Basic EPS | 48.68% | 64.74% | 61.91% | 51.11% | 42.41% |
| EPS Diluted | 48.16% | 64.32% | 61.20% | 53.05% | 44.89% |
| Normalized Diluted EPS | 48.68% | 64.74% | 61.91% | 51.11% | 42.41% |
| Average Basic Shares Outstanding | 2.96% | 4.40% | 6.08% | 7.82% | 9.89% |
| Average Diluted Shares Outstanding | 2.96% | 4.40% | 6.08% | 7.82% | 9.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |